According to a new report, published by KBV research, The Global Musculoskeletal Disorders Drugs Market size is expected to reach $109.4 billion by 2029, rising at a market growth of 4.2% CAGR during the forecast period.
The Hospital Pharmacies market is showcasing a CAGR of 4.7% during (2023 - 2029). This is due to the growing awareness and increased clinical and hospital visits. In addition, an important aspect fueling the segment's rise is the aging population. This is because elderly people are frequently admitted to hospitals for various chronic conditions like musculoskeletal disorders, for which they are given medicine after the prescription is attained from hospitals. Hence, the mentioned factors are expected to propel the hospital pharmacy market segment's growth in the projected period.
The Parenteral market has acquired the maximum revenue share in the Global Musculoskeletal Disorders Drugs Market by Route of Administration in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $76.3 billion by 2029. This is due to the fact that drugs that are inert, poorly absorbed, or ineffective when administered orally can be administered by parenteral. Parenteral drug administration can refer to any non-oral delivery route, but it is typically understood as intravenous injections that skip the skin and mucous membranes. This route of administration can be used to ensure a slow or delayed beginning of effect and prevent patient concordance issues, which in turn aids the segment's growth.
The DMARDs market has shown the high growth rate of 4.4% during (2023 - 2029). This is because DMARDs govern the immune system's overreaction to stimuli. In addition to reducing or preventing joint deterioration, they aid in the relief of pain and inflammation. For many different musculoskeletal problems, they are a long-term treatment. They don't just treat the symptoms; they also try to change the way the disease works. Hence, the mentioned characteristics of the DMARDs will propel the segment's growth.
The North America market dominated the Global Musculoskeletal Disorders Drugs Market by Region in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $38.5 billion by 2029. The Asia Pacific market is anticipated to grow at a CAGR of 5.1% during (2023 - 2029). Additionally, The Europe market would witness a CAGR of 3.6% during (2023 - 2029).
Full Report: https://www.kbvresearch.com/musculoskeletal-disorders-drugs-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AbbVie, Inc., Amgen, Inc., Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and UCB S.A.
By Distribution Channel
By Route of Administration
By Drug Type
By Geography
Companies Profiled
Unique Offerings 
